Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are...
Transcript of Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are...
![Page 1: Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts](https://reader034.fdocuments.us/reader034/viewer/2022051905/5ff70ffd7cadf177d236725d/html5/thumbnails/1.jpg)
Steps to Reducing Barriersto Biosimilars in the United States
Alex BrillMatrix Global AdvisorsGRx+Biosims 2018 | Baltimore, MD | September 6, 2018
![Page 2: Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts](https://reader034.fdocuments.us/reader034/viewer/2022051905/5ff70ffd7cadf177d236725d/html5/thumbnails/2.jpg)
Overview
• Biosimilars Landscape• Barriers to Biosimilars by Category
1. Reference Product Manufacturers2. Biosimilar Manufacturers3. Policy4. Stakeholder Education and Awareness
• Tipping Points for Biosimilars• Strategies for Overcoming Barriers
2
![Page 3: Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts](https://reader034.fdocuments.us/reader034/viewer/2022051905/5ff70ffd7cadf177d236725d/html5/thumbnails/3.jpg)
Landscape: U.S. Sales of Reference Biologics
3
Source: IQVIA Institute for Human Data Science.
![Page 4: Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts](https://reader034.fdocuments.us/reader034/viewer/2022051905/5ff70ffd7cadf177d236725d/html5/thumbnails/4.jpg)
Landscape: U.S. Biosimilars Approved
4
![Page 5: Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts](https://reader034.fdocuments.us/reader034/viewer/2022051905/5ff70ffd7cadf177d236725d/html5/thumbnails/5.jpg)
Landscape: U.S. Biosimilars in Development
5
Source: FDA.
![Page 6: Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts](https://reader034.fdocuments.us/reader034/viewer/2022051905/5ff70ffd7cadf177d236725d/html5/thumbnails/6.jpg)
Barriers to Biosimilars by Category
#1: Reference Product Manufacturers
• Rebate practices
• Lifecycle management (e.g., late-stage patents)
#2: Biosimilar Manufacturers
• Market uncertainty
• Limited discounting and low volume6
![Page 7: Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts](https://reader034.fdocuments.us/reader034/viewer/2022051905/5ff70ffd7cadf177d236725d/html5/thumbnails/7.jpg)
Barriers to Biosimilars by Category
#3: Policy
• Patent thickets
• FDA guidance
#4: Stakeholder Education and Awareness
• Lack of education and awareness
• Limited prescribing experience7
![Page 8: Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts](https://reader034.fdocuments.us/reader034/viewer/2022051905/5ff70ffd7cadf177d236725d/html5/thumbnails/8.jpg)
Tipping Points for Biosimilars
Market, regulatory, legal, perception, and reimbursement issues are reduced so biosimilars can enter the market with ease
Sufficient competition to a reference biologic exists to achieve meaningful savings
8
![Page 9: Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts](https://reader034.fdocuments.us/reader034/viewer/2022051905/5ff70ffd7cadf177d236725d/html5/thumbnails/9.jpg)
Strategies to Overcome Barriers, by Category
#1: Reference Product Manufacturers
Brand biologics manufacturers use contracting practices and lifecycle management strategies to protect market share, including penalties for customers who move patients to a biosimilar and additional patents late in a reference product’s life
Strategies• Payors: Adopt longer-term perspective in contracts/formularies• Employers: Identify cost-saving opportunities• Policymakers: Ensure fair market access for biosimilars
9
![Page 10: Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts](https://reader034.fdocuments.us/reader034/viewer/2022051905/5ff70ffd7cadf177d236725d/html5/thumbnails/10.jpg)
Strategies to Overcome Barriers, by Category
#2: Biosimilar Manufacturers
Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts at launch have not been steep enough to capture market share
Strategies• Payors: Institute policies to drive biosimilar utilization• Biosimilar manufacturers: Offer competitive contracting terms• Employers: Require biosimilar coverage in contracts
10
![Page 11: Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts](https://reader034.fdocuments.us/reader034/viewer/2022051905/5ff70ffd7cadf177d236725d/html5/thumbnails/11.jpg)
Strategies to Overcome Barriers, by Category
#3: Policy
The threat of patent litigation can deter biosimilar development; lack of guidance on interchangeability and state restrictions on substitution will limit development
Strategies• Congress: Limit frivolous late-stage patents• FDA: Continue to support and clarify interchangeability
11
![Page 12: Steps to Reducing Barriers to Biosimilars in the United States · 2018. 9. 11. · Biosimilars are expensive to develop, the market is uncertain, and biosimilars’ price discounts](https://reader034.fdocuments.us/reader034/viewer/2022051905/5ff70ffd7cadf177d236725d/html5/thumbnails/12.jpg)
Strategies to Overcome Barriers, by Category
#4: Stakeholder Education and Awareness
Physicians, patients, and employers lack awareness about the safety of and savings opportunity from biosimilars
Strategies• Biosimilar manufacturers: Provide patient and physician education• Payors: Incentivize stakeholders to gain experience• Employers: Share biosimilar savings with employees• Policymakers: Promote biosimilars as safe and effective
12